CELZ News and Press, Creative Medical Technology Holdings Inc. From 04/12/23

2023-04-12 09:14:56 ET Creative Medical Technology ( NASDAQ: CELZ ) stock soared ~150% premarket on Wednesday after the company said that one-year follow-up data confirmed significant efficacy and no serious adverse effects in patients using CELZ-001 to treat Type 2 Diabetes. ...

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study PR Newswire -- One-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients Using CELZ-001 for Treating Type 2 Diabetes -- PHOENIX , Ap...

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update PR Newswire PHOENIX , April 4, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company" or "We") (NASDA...

2023-03-23 09:24:09 ET Creative Medical Technology ( NASDAQ: CELZ ) said it filed an application to U.S. Food and Drug Administration (FDA) seeking orphan drug designation (ODD) for its ImmCelz (CELZ-100) platform to treat Brittle Type 1 Diabetes. The company noted that...

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes PR Newswire PHOENIX , March 23, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ...

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development PR Newswire Independent Studies Validate Enhanced Clinical Grade Cell Production for Patient Use in Multiple Indications at a Fraction of Current Industry Cost PHOE...

CELZ-201 is the First Novel Allogenic Cellular Therapy in the Dorsal Artery of the Pancreas in the United States Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care...

Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced positive three-year follow-u...

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) reported that it has received Institutional Review Board approval to proceed with its clinical trial to treat Type 1 Diabetes with its CELZ-201 cell therapy. The U.S. FDA had previously cleared the Company’s investigational ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Billion Photos / Shutterstock Creative Medical (NASDAQ: CELZ ) stock is rocketing higher on Wednesday thanks to clearance for a new clinical trial . That clearance comes from the FDA and covers CELZ-...